CA2345638A1 - Formes posologiques a administration par voie orale contenant le compose (2s,3s,5r)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol et une quantite stabilisante efficace d'acide alginique - Google Patents

Formes posologiques a administration par voie orale contenant le compose (2s,3s,5r)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol et une quantite stabilisante efficace d'acide alginique Download PDF

Info

Publication number
CA2345638A1
CA2345638A1 CA002345638A CA2345638A CA2345638A1 CA 2345638 A1 CA2345638 A1 CA 2345638A1 CA 002345638 A CA002345638 A CA 002345638A CA 2345638 A CA2345638 A CA 2345638A CA 2345638 A1 CA2345638 A1 CA 2345638A1
Authority
CA
Canada
Prior art keywords
oral dosage
dosage form
discrete oral
discrete
alginic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002345638A
Other languages
English (en)
Inventor
Samuel Bruce Balik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2345638A1 publication Critical patent/CA2345638A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des formes posologiques discrètes à administration par voie orale, généralement des comprimés ou des gélules, contenant le composé (2S,3S,5R)-2-(3,5-difluorophényl)-3,5-diméthyl-2-morpholinol ou un sel ou solvate physiologiquement acceptable de ce composé, ou un solvate dudit sel, et une quantité stabilisante efficace d'acide alginique. Ces formes posologiques sont utiles pour prévenir ou traiter l'hypercinésie avec déficit de l'attention ou la dépression, ou pour traiter l'accoutumance à des produits contenant de la nicotine, en particulier des produits contenant du tabac, afin d'aider, par exemple, un patient à s'arrêter de fumer.
CA002345638A 1998-09-28 1999-09-24 Formes posologiques a administration par voie orale contenant le compose (2s,3s,5r)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol et une quantite stabilisante efficace d'acide alginique Abandoned CA2345638A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10211298P 1998-09-28 1998-09-28
US60/102,112 1998-09-28
PCT/EP1999/007117 WO2000018406A1 (fr) 1998-09-28 1999-09-24 Formes posologiques a administration par voie orale contenant le compose (2s,3s,5r)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol et une quantite stabilisante efficace d'acide alginique

Publications (1)

Publication Number Publication Date
CA2345638A1 true CA2345638A1 (fr) 2000-04-06

Family

ID=22288187

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002345638A Abandoned CA2345638A1 (fr) 1998-09-28 1999-09-24 Formes posologiques a administration par voie orale contenant le compose (2s,3s,5r)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol et une quantite stabilisante efficace d'acide alginique

Country Status (17)

Country Link
EP (1) EP1117407A1 (fr)
JP (1) JP2002525328A (fr)
KR (1) KR20010075385A (fr)
CN (1) CN1328459A (fr)
AR (1) AR022673A1 (fr)
AU (1) AU6087399A (fr)
BR (1) BR9914096A (fr)
CA (1) CA2345638A1 (fr)
CZ (1) CZ20011142A3 (fr)
HU (1) HUP0103459A2 (fr)
IL (1) IL142054A0 (fr)
MA (1) MA26693A1 (fr)
NO (1) NO20011555D0 (fr)
PE (1) PE20001087A1 (fr)
PL (1) PL346877A1 (fr)
TR (1) TR200100863T2 (fr)
WO (1) WO2000018406A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1220673A2 (fr) * 1999-10-13 2002-07-10 Glaxo Group Limited Methode destinee au traitement de l'obesite
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4597969A (en) * 1982-04-05 1986-07-01 Merck Sharp & Dohme Stabilization of unstable drugs or food supplements
GB8924528D0 (en) * 1989-10-31 1989-12-20 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use

Also Published As

Publication number Publication date
PL346877A1 (en) 2002-03-11
TR200100863T2 (tr) 2001-07-23
AR022673A1 (es) 2002-09-04
BR9914096A (pt) 2001-07-31
CZ20011142A3 (cs) 2001-09-12
JP2002525328A (ja) 2002-08-13
WO2000018406A1 (fr) 2000-04-06
HUP0103459A2 (hu) 2002-01-28
NO20011555L (no) 2001-03-27
PE20001087A1 (es) 2000-10-20
EP1117407A1 (fr) 2001-07-25
AU6087399A (en) 2000-04-17
IL142054A0 (en) 2002-03-10
MA26693A1 (fr) 2004-12-20
KR20010075385A (ko) 2001-08-09
NO20011555D0 (no) 2001-03-27
CN1328459A (zh) 2001-12-26

Similar Documents

Publication Publication Date Title
KR20100121509A (ko) 구강 내 붕괴정
CA2685131C (fr) Preparation solide stable comprenant un derive de 4,5-epoxymorphinane
CN101925349A (zh) 替马西泮的口腔崩解片组合物
CA2687124A1 (fr) Formulations de doxepine a faible dose, incluant des formulations buccales, sublinguales et a dissolution rapide, et leurs utilisations pour traiter l'insomnie
JP2012001473A (ja) 固形製剤
KR20060065628A (ko) 레보타이록신 나트륨을 포함하는 제약 제제
JP2009513530A5 (fr)
JP6019116B2 (ja) （トリメトキシフェニルアミノ）ピリミジニル製剤
WO2002058666A2 (fr) Procede pour la preparation d'une composition de valproate de sodium non hygroscopique
WO2007058397A1 (fr) Comprime dispersible comportant le melange d'amoxicilline et d'acide clavulanique ou ses sels et son procede de preparation
EP4062906A1 (fr) Composition pharmaceutique orale comprenant un composé carbamate et procédé de préparation de cette composition
IL106743A (en) Tablets with enhanced bioavailability of claudonic acid
JP5318400B2 (ja) レボフロキサシン含有錠剤
WO2011005250A1 (fr) Formulations de 6-(5-chloro-2-pyridyl)-5-[(4-méthyl-1-pipérazinyl) carbonyloxy]-7-oxo-6,7-dihydro-5h-pyrrolo[3,4-b]pyrazine
EP3437645B1 (fr) Comprimé enrobé d'un film et présentant une stabilité chimique élevée de son principe actif
EP2491933A1 (fr) Composition pharmaceutique pour administration orale
JP5295506B2 (ja) レボフロキサシン含有錠剤
EP3501506B1 (fr) Composition de comprimé pharmaceutique comprenant du brexpiprazole
CA2345638A1 (fr) Formes posologiques a administration par voie orale contenant le compose (2s,3s,5r)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol et une quantite stabilisante efficace d'acide alginique
MXPA01003130A (en) Oral dosage formulations comprising (2s,3s,5r) -2-(3,5- difluorophenyl) -3,5-dimethyl -2-morpholinol and an effective stabilizing amount of alginic acid
JPWO2003075919A1 (ja) 塩酸ピルジカイニド含有錠剤（乾式）
JP7195660B1 (ja) 口腔内崩壊錠
JP4393119B2 (ja) ヨウ化イソプロパミド含有製剤
WO2022138717A1 (fr) Préparation solide orale
JP2024520860A (ja) 固体剤形のメラトニン製剤

Legal Events

Date Code Title Description
FZDE Discontinued